Real-world outcomes of talimogene laherparepvec as salvage therapy for advanced melanoma
This study demonstrates T-VEC's potential efficacy in achieving meaningful disease control and response durability in patients with unresectable and/or metastatic melanoma, including those with diverse prior-treatment histories and comorbidities.
Authors
- Coley Doolittle‐Amieva
- Evan Hall (ORCID: https://orcid.org/0000-0002-0305-7745)
- Rita E. Chen (ORCID: https://orcid.org/0000-0002-5100-7750)
- Di Chen (ORCID: https://orcid.org/0000-0001-9509-2814)
- George Ansstas (ORCID: https://orcid.org/0000-0002-7178-8777)
- Ted Gooley
- Song Y Park
- Melissa M Yamada
- Smitha Chandrasekhar
- Paul T Nghiem
- Shailender Bhatia
Institutions
- University of Washington (US)
- Washington University in St. Louis (US)
- Fred Hutch Cancer Center (US)
- Saint Louis University (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1136/jitc-2025-013564
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Prostate Cancer Foundation
- National Institutes of Health
- National Cancer Institute